SCHEMBL21144199

SCHEMBL21144199

FCc1ccn(-c2nc(Cl)cc(NC3CCC(F)CC3)n2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 1/20 0.36
CDC7 O00311 5/20 0.33
GSK3B P49841 5/20 0.33
DAPK3 O43293 4/20 0.33
PAK4 O96013 4/20 0.33
PRKACA P17612 4/20 0.33
CDK8 P49336 4/20 0.33
PRKX P51817 4/20 0.33
MAP4K2 Q12851 4/20 0.33
STK3 Q13188 4/20 0.33
DYRK1A Q13627 4/20 0.33
MELK Q14680 4/20 0.33
MINK1 Q8N4C8 4/20 0.33
HIPK2 Q9H2X6 4/20 0.33
CLK4 Q9HAZ1 4/20 0.33
MAP4K5 Q9Y4K4 4/20 0.33
CDK2 P24941 4/20 0.33
CDK5 Q00535 4/20 0.33
ROCK2 O75116 3/20 0.33
PRKD3 O94806 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686558 0.87 IDH1 (0.47) OPRK1MAPK8IDH1
SCHEMBL21143867 0.84 KCNN3 (0.38) OPRK1CDC7GSK3BDAPK3PAK4
SCHEMBL21143777 0.84 PTGS2 (0.36) OPRK1
SCHEMBL21165822 0.81 PIK3CA (0.40) MAPK1MEN1KMT2A
SCHEMBL31127184 0.81 PIM1 (0.42) OPRK1CDC7GSK3BDAPK3PAK4
SCHEMBL21143902 0.81 PIM1 (0.42) OPRK1CDC7GSK3BDAPK3PAK4
SCHEMBL19686822 0.78 IDH1 (0.47) OPRK1CDK2CDK5IDH1CCNA2
SCHEMBL19687320 0.74 IDH1 (0.47) IDH1MEN1KMT2AKCNN2KCNN3
SCHEMBL19687162 0.73 IDH1 (0.46) MAPK8IDH1
SCHEMBL21143804 0.73 PIM1 (0.43) CDC7GSK3BDAPK3PAK4PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 OPRK1 337/4885CDC7 3353/4885GSK3B 2806/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 OPRK1 337/4885CDC7 3353/4885GSK3B 2806/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 OPRK1 337/4885CDC7 3353/4885GSK3B 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.